Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment

J Acquir Immune Defic Syndr. 2015 Mar 1;68(3):310-3. doi: 10.1097/QAI.0000000000000476.

Abstract

In HIV-1-infected treatment-naive patients with mild-to-moderate renal impairment [creatinine clearance (CrCl): 50-89 mL/min], elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB, n = 33) achieved high rates of virologic success (78.8%; 95% confidence interval: 61.1% to 91.0%) and was well tolerated through week 48. Four patients discontinued study drug due to an adverse event and none due to proximal renal tubulopathy. As expected, decreases in CrCl were noted as early as week 2, after which they stabilized. The renal safety profile of STB in patients from this study is consistent with the long-term experience in a large number of patients with CrCl ≥70 mL/min.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / adverse effects
  • Adenine / analogs & derivatives
  • Adenine / therapeutic use
  • Adult
  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / therapeutic use*
  • Carbamates / adverse effects
  • Carbamates / therapeutic use
  • Cobicistat
  • Cohort Studies
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / therapeutic use
  • Emtricitabine
  • Female
  • HIV Infections / complications*
  • HIV Infections / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Organophosphonates / adverse effects
  • Organophosphonates / therapeutic use
  • Quinolones / adverse effects
  • Quinolones / therapeutic use
  • Renal Insufficiency / chemically induced*
  • Renal Insufficiency / pathology*
  • Tenofovir
  • Thiazoles / adverse effects
  • Thiazoles / therapeutic use
  • Treatment Outcome

Substances

  • Anti-HIV Agents
  • Carbamates
  • JTK 303
  • Organophosphonates
  • Quinolones
  • Thiazoles
  • Deoxycytidine
  • Tenofovir
  • Emtricitabine
  • Adenine
  • Cobicistat